Your SlideShare is downloading. ×
20110301_EN
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

20110301_EN

354
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
354
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Daiichi Sankyo To Acquire Plexxikon Inc.  “Building a world class oncology pipeline by 2015” March 1, 2011 Joji Nakayama President and CEO Daiichi Sankyo Co., LTD.
  • 2. Agenda1.Strategic Rationale2.Plexxikon’s Profile3.Financial Conditions 1
  • 3. Strategic Rationale 
  • 4. Our Oncology StrategyBuilding a world class pipeline by 2015 Secure market presence Accelerate proof‐of‐concept trial launches Accelerate market launches for new products and indications Reinforce pipelines with multiple new chemical entities (NCE) Enhance world class drug discovery capabilities and organization Undertake internal projects Secure external resources through in‐licensing and M&As Establish R&D capabilities and technological foundations to  underpin sustainable growth 3
  • 5. Oncology Pipeline Collaborations Exploratory stage Preclinical stage Phase  I Phase  II Phase III Application ARQ 197Small molecules AKIPTM c‐MET inhibitor Scaffold-Based PLX3397 PLX4032 Drug DiscoveryTM FMS/KIT BRAF Efatutazone PPARγ Nimotuzumab Denosumab EGFR Ab RANKL AbAntibodies Innovative antibodies Alliance for antibody  Technology U3‐1565 U3‐1287 HB‐EGF Ab HER3 Ab Tigatuzumab DR5 Ab In‐house projects In‐licensed projects U3/Plexxikon projects 4
  • 6. Robust Pipeline of Plexxikon PhaseProducts bytherapeutic area Indication Preclinical Phase 1 Phase 2 Phase 3Oncology PLX4032 Melanoma Colorectal Cancer PLX3397 Metastatic Breast CancerInflammation PLX5622 Rheumatoid Arthritis Kinase inhibitor Systemic Lupus ErythematosusCardio-renal Polycystic Kidney Kinase inhibitor Disease Protease inhibitor HypertensionCNS Kinase inhibitor Alzheimer’s Disease Kinase inhibitor Multiple Sclerosis 5
  • 7. Plexxikon’s Technical ApproachScaffold Based Drug DiscoveryTM Screening of “Scaffold” based library, followed by high purity protein purification, and high throughput co-crystallography of drugs and targets ▪ Novel chemical space ▪ IP ▪ Small molecular weight ▪ Formulation components ▪ Targeting; selectivity vs. ▪ Precision chemistry potency ▪ Family of proteins ▪ Beyond oncology 6
  • 8. Global Research Structure < Japan > Daiichi Sankyo Daiichi Sankyo RD Associe Asubio Pharma RCI* Global Development Plexxikon< India > < US > U3 Pharma < EU >* Daiichi Sankyo Life Science Research Centre in India  7
  • 9. Plexxikon’s Profile
  • 10. Plexxikon at a Glance Established in 2001 Private company (not listed) Location:  Berkeley, CA CEO: K. Peter Hirth, Ph.D.  Approximately 45 employees R&D areas:  Oncology, Inflammation, Cardio‐renal, CNS  9
  • 11. Plexxikon is an Attractive Opportunity Talent/ networks Strong internal and external scientific talent Filing for EU and US marketing approval anticipated in  Market entry 2011  Commercial and Development partnership with Roche High growth indication Melanoma is a leading oncology growth indication Portfolio fit Opportunity to build a platform for personalized  medicine R&D footprint U.S. R&D presence in biotech Bay Area compliments  our global strategy  10
  • 12. The San Francisco Bay Area Marin Solano Pharmaceutical Company Top-tier university San Francisco Contra Costa California is one of the most  Alameda active life‐science states in the  US San Mateo San Francisco Bay Area offers  Santa Cruz Santa Clara strong community of biotech,  and three world‐class  universities 11
  • 13. About PLX4032 Initial target indication: metastatic melanoma    expressing the BRAF mutation Current stage: Phase III (BRIM3 trial) • An interim analysis of this Phase III showed the study met the   pre‐specified primary endpoint (OS & PFS) ( Plexxikon announced in 18 January, 2011) Development and commercialization partner: Roche Co‐developing diagnostic with Roche Molecular  Diagnostic Filing for EU and US marketing approval anticipated in  2011  12
  • 14. Rights Obtained for PLX4032 Revenue is from running royalties Upon FDA approval, Daiichi Sankyo, Inc., will  co‐promote PLX4032 with Roche in the U.S. 13
  • 15. Financial Conditions
  • 16. Financial ConditionsDaiichi Sankyo has agreed with Plexxikon’s shareholders to acquire all shares of Plexxikon Daiichi Sankyo will pay US$805 million at closingDaiichi Sankyo will pay up to an additional US$130 million to current Plexxikon’s shareholders in milestone payments.Details of the financial calculation will be announced once finalized 15
  • 17. Memo 15
  • 18. Memo 15
  • 19. Contact address regarding this material DAIICHI SANKYO CO., LTD. Corporate Communications Department TEL: +81-3-6225-1126Each numerical value regarding the future prospect in this material is derived from our judgmentand assumptions based on the currently available information and may include risk and uncertainty.For this reason, the actual performance data, etc. may differ from the prospective value. 19

×